HRP20150192T1 - Lijeäśenje i prevencija hiv infekcije - Google Patents
Lijeäśenje i prevencija hiv infekcije Download PDFInfo
- Publication number
- HRP20150192T1 HRP20150192T1 HRP20150192AT HRP20150192T HRP20150192T1 HR P20150192 T1 HRP20150192 T1 HR P20150192T1 HR P20150192A T HRP20150192A T HR P20150192AT HR P20150192 T HRP20150192 T HR P20150192T HR P20150192 T1 HRP20150192 T1 HR P20150192T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- formulation
- brecanavir
- months
- time interval
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 claims 6
- 229950009079 brecanavir Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920002517 Poloxamer 338 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000036267 drug metabolism Effects 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- -1 fatty acid esters Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000008092 positive effect Effects 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000008137 solubility enhancer Substances 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Upotreba parenteralne formulacije koja sadrži anti-virusno učinkovitu količinu brekanavira ili njegovu farmaceutski prihvatljivu kiselu adicijsku sol, te nosač, bez dodatnog sredstva koje ima pozitivan učinak na metabolizam lijeka i/ili farmakokinetiku da bi se pospješila bioraspoloživost pri čemu je dodatno sredstvo ritonavir naznačena time da je za proizvodnju medikamenta za liječenje subjekta koji je zaražen HIV-om, pri čemu se formulacija treba davati intramuskularnom ili potkožnom injekcijom naizmjenično u vremenskom intervalu koji je u rasponu od dva tjedna do jedne godine.
2. Upotreba prema zahtjevu 1, naznačena time da je parenteralna formulacija otopina koja sadrži učinkovitu količinu brekanavira i vodeni nosač.
3. Upotreba prema zahtjevu 2, naznačena time da se u navedenu otopinu dodaje pospješivač topivosti ili surfaktant.
4. Upotreba prema bilo kojem zahtjevu od 1 - 3, naznačena time da se formulacija treba davati u vremenskom intervalu koji je u rasponu od dva tjedna do jednog mjeseca.
5. Upotreba prema bilo kojem zahtjevu od 1 - 3, naznačena time da se formulacija treba davati u vremenskom intervalu koji je u rasponu od jednog mjeseca do tri mjeseca.
6. Upotreba prema bilo kojem zahtjevu od 1 - 3, naznačena time da se formulacija treba davati u vremenskom intervalu koji je u rasponu od tri mjeseca do šest mjeseci.
7. Upotreba prema bilo kojem zahtjevu od 1 - 3, naznačena time da se formulacija treba davati jednom svaki mjesec.
8. Upotreba prema bilo kojem zahtjevu od 1 - 3, naznačena time da se formulacija treba davati jednom svaka tri mjeseca.
9. Upotreba prema zahtjevu 1 naznačena time da se razina u krvnoj plazmi održava na razini iznad 28 ng/ml.
10. Farmaceutski pripravak za davanje intramuskularnom ili potkožnom injekcijom, koji sadrži terapeutski učinkovitu količinu brekanavira ili njegove soli, u obliku suspenzije mikro- ili nanočestica naznačen time da sadrži:
(a) brekanavir ili njegovu sol, u obliku mikro- ili nanočestica, koje imaju površinski modifikator adsorbiran na njihovoj površini; te
(b) farmaceutski prihvatljiv vodeni nosač; pri čemu je aktivni sastojak brekanavira suspendiran.
11. Pripravak prema zahtjevu 10, naznačen time da je površinski modifikator odabran iz skupine koju čine poloksameri, α-tokoferil polietilen glikol sukcinati, esteri masne kiseline polioksietilen sorbitana, te soli negativno nabijenih fosfolipida.
12. Pripravak prema zahtjevima 10 ili 11, naznačen time da je površinski modifikator odabran iz skupine koju čine poloksamer 338, vitamin E-TGPS, polisorbat-80, polisorbat-20 i natrijev fosfatidil-glicerol iz jaja.
13. Pripravak prema bilo kojem zahtjevu od 10 do 12, naznačen time da je prosječna efektivna veličina čestica mikro- ili nanočestica brekanavira ispod 200 nm.
14. Upotreba prema bilo kojem zahtjevu od 1 do 3, naznačena time da je parenteralna formulacija farmaceutski pripravak kao što je definirano u bilo kojem zahtjevu od 10 do 13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170916 | 2009-09-22 | ||
| PCT/EP2010/063930 WO2011036159A2 (en) | 2009-09-22 | 2010-09-22 | Treatment and prevention of hiv infection |
| EP10762626.9A EP2480220B1 (en) | 2009-09-22 | 2010-09-22 | Treatment and prevention of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150192T1 true HRP20150192T1 (hr) | 2015-04-10 |
Family
ID=41466671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150192AT HRP20150192T1 (hr) | 2009-09-22 | 2015-02-19 | Lijeäśenje i prevencija hiv infekcije |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20120201868A1 (hr) |
| EP (1) | EP2480220B1 (hr) |
| JP (1) | JP5897465B2 (hr) |
| KR (2) | KR101845811B1 (hr) |
| CN (1) | CN102573815B (hr) |
| AU (1) | AU2010299959B2 (hr) |
| BR (1) | BR112012006345A2 (hr) |
| CA (1) | CA2774750C (hr) |
| DK (1) | DK2480220T3 (hr) |
| ES (1) | ES2530941T3 (hr) |
| HK (1) | HK1174256A1 (hr) |
| HR (1) | HRP20150192T1 (hr) |
| MX (1) | MX2012003424A (hr) |
| PL (1) | PL2480220T3 (hr) |
| RU (1) | RU2569058C2 (hr) |
| WO (1) | WO2011036159A2 (hr) |
| ZA (1) | ZA201202070B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022003945A (es) * | 2019-10-01 | 2022-04-25 | Viiv Healthcare Co | Metodo para tratar vih con cabotegravir y rilpivirina. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| AR031520A1 (es) | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
| US7220768B2 (en) * | 2003-02-11 | 2007-05-22 | Wyeth Holdings Corp. | Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus |
| JP5754005B2 (ja) * | 2006-01-20 | 2015-07-22 | ヤンセン・アールアンドデイ・アイルランド | Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置 |
| WO2009007441A2 (en) * | 2007-07-12 | 2009-01-15 | Tibotec Pharmaceuticals Ltd. | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
-
2010
- 2010-09-22 BR BR112012006345-6A patent/BR112012006345A2/pt not_active Application Discontinuation
- 2010-09-22 DK DK10762626.9T patent/DK2480220T3/en active
- 2010-09-22 AU AU2010299959A patent/AU2010299959B2/en not_active Ceased
- 2010-09-22 EP EP10762626.9A patent/EP2480220B1/en active Active
- 2010-09-22 KR KR1020177036213A patent/KR101845811B1/ko active IP Right Grant
- 2010-09-22 KR KR1020127008150A patent/KR101811314B1/ko active IP Right Grant
- 2010-09-22 CA CA2774750A patent/CA2774750C/en active Active
- 2010-09-22 WO PCT/EP2010/063930 patent/WO2011036159A2/en active Application Filing
- 2010-09-22 JP JP2012529305A patent/JP5897465B2/ja active Active
- 2010-09-22 CN CN201080042909.3A patent/CN102573815B/zh active Active
- 2010-09-22 PL PL10762626T patent/PL2480220T3/pl unknown
- 2010-09-22 MX MX2012003424A patent/MX2012003424A/es active IP Right Grant
- 2010-09-22 US US13/497,719 patent/US20120201868A1/en not_active Abandoned
- 2010-09-22 RU RU2012116070/15A patent/RU2569058C2/ru active
- 2010-09-22 ES ES10762626T patent/ES2530941T3/es active Active
-
2012
- 2012-03-20 ZA ZA2012/02070A patent/ZA201202070B/en unknown
-
2013
- 2013-01-29 HK HK13101244.7A patent/HK1174256A1/xx not_active IP Right Cessation
-
2015
- 2015-02-19 HR HRP20150192AT patent/HRP20150192T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101811314B1 (ko) | 2017-12-26 |
| JP2013505224A (ja) | 2013-02-14 |
| HK1174256A1 (en) | 2013-06-07 |
| WO2011036159A3 (en) | 2011-11-24 |
| KR20170141825A (ko) | 2017-12-26 |
| CN102573815B (zh) | 2015-09-30 |
| WO2011036159A2 (en) | 2011-03-31 |
| KR101845811B1 (ko) | 2018-05-18 |
| BR112012006345A2 (pt) | 2020-08-11 |
| EP2480220B1 (en) | 2014-11-19 |
| ZA201202070B (en) | 2013-08-28 |
| KR20120093850A (ko) | 2012-08-23 |
| AU2010299959A1 (en) | 2012-03-01 |
| RU2012116070A (ru) | 2013-10-27 |
| EP2480220A2 (en) | 2012-08-01 |
| PL2480220T3 (pl) | 2015-10-30 |
| CA2774750A1 (en) | 2011-03-31 |
| AU2010299959B2 (en) | 2016-07-21 |
| ES2530941T3 (es) | 2015-03-09 |
| CN102573815A (zh) | 2012-07-11 |
| RU2569058C2 (ru) | 2015-11-20 |
| DK2480220T3 (en) | 2015-02-23 |
| JP5897465B2 (ja) | 2016-03-30 |
| MX2012003424A (es) | 2012-05-08 |
| CA2774750C (en) | 2017-11-28 |
| US20120201868A1 (en) | 2012-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khatoon et al. | Proniosomes derived niosomes: recent advancements in drug delivery and targeting | |
| Gaur et al. | Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies | |
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| Hu et al. | Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy | |
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| HRP20240058T1 (hr) | Formulacije bedakvilina s dugotrajnim djelovanjem | |
| JP2016503030A5 (hr) | ||
| HRP20130544T4 (hr) | Dugoročno liječenje hiv-infekcije sa tcm278 | |
| US10092523B2 (en) | Long acting pharmaceutical compositions | |
| ES2686295T3 (es) | N-Acetil-DL-leucina, medicamento neuroprotector y retinoprotector | |
| JP2009102342A5 (hr) | ||
| JP2012180381A5 (hr) | ||
| RU2015115127A (ru) | Жидкие лекарственные композиции апиксабана | |
| MY160652A (en) | Pharmaceutical composition for oral administration | |
| JP2017528497A5 (hr) | ||
| TWI813571B (zh) | 防沉澱的小分子藥調配物 | |
| Hassan et al. | Antiviral nanodelivery systems: current trends in acyclovir administration | |
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
| US20110318298A1 (en) | Viral infection therapeutic drug containing polyalkyleneimine | |
| Zakaria et al. | Boosting the anti MERS-CoV activity and oral bioavailability of resveratrol via PEG-stabilized emulsomal nano-carrier: factorial design, in-vitro and in-vivo assessments | |
| HRP20150192T1 (hr) | Lijeäśenje i prevencija hiv infekcije | |
| Chinaeke et al. | Formulation of novel artesunate-loaded solid lipid microparticles (SLMs) based on dika wax matrices: in vitro and in vivo evaluation | |
| CN101229131A (zh) | 具有降低喜树碱类药物胃肠毒性的新型纳米微粒制剂 | |
| de Souza et al. | Antiviral and antimicrobial (antibacterial) potentiality of nano drugs |